Biogen Extends Felzartamab Kidney Transplant Rejection Trial Into Four-Year Long-Term Safety Study
核心洞察
Biogen has extended its felzartamab program with an open-label long-term extension study in kidney transplant patients who developed antibody-mediated rejection (搜索) or microvascular inflammation in the TRANSCEND or TRANSPIRE trials.
Felzartamab is administered as a slow intravenous infusion every eight weeks and is designed to calm immune attacks on transplanted kidneys, with safety as the study's primary goal.
Biogen executives describe antibody-mediated rejection (搜索) as the foundational opportunity for felzartamab, noting there are no approved therapies and roughly 11,000 U.S. patients experience secondary kidney transplant rejection.
Biogen Inc. has extended clinical development of its transplant immunology asset felzartamab, opening a long-term extension study in kidney transplant recipients who previously showed antibody-mediated rejection (搜索) (AMR) or microvascular inflammation in the company's TRANSCEND or TRANSPIRE trials. The study, formally titled "An Open-Label Long-Term Extension Study of Felzartamab in Participants With Antibody-Mediated Rejection or Microvascular Inflammation Previously Enrolled in TRANSCEND or TRANSPIRE," is designed to track long-run safety and outcomes in this high-risk population.
Trial Design and Dosing
The extension is an interventional, open-label study, meaning participants and investigators know whether patients are receiving felzartamab or undergoing monitoring only. All participants enter a single treatment group with no randomization, and the primary goal is treatment safety rather than a direct comparison against another therapy.
Felzartamab is an antibody drug given by slow infusion into a vein every eight weeks. It is designed to calm immune attacks on transplanted kidneys and may help preserve kidney function in patients facing late rejection or ongoing microvascular damage.
The trial enrolls patients who completed Biogen's prior TRANSCEND and TRANSPIRE studies and follows them for up to approximately four years. Some participants continue felzartamab infusions with as many as 27 visits, while others attend only monitoring visits if they discontinued the drug in the parent trials.
The study was first submitted on February 26, 2026, and the most recent update on August 4, 2026, confirms the protocol is active and being refined as Biogen builds a broader program for long-term use in organ transplant settings. Primary completion and full completion dates are not yet listed, indicating that key efficacy and safety readouts remain several years away.
The AMR Opportunity
According to Biogen executive Keeney, felzartamab's initial focus is antibody-mediated rejection (搜索) in kidney transplantation. He stated that there are no approved therapies for AMR and that approximately 11,000 U.S. patients experience secondary rejection of their kidney transplants. Keeney described AMR as the "foundational opportunity" for felzartamab.
Beyond transplant rejection, Biogen plans to evaluate felzartamab in IgA nephropathy (搜索), membranous nephropathy (搜索) and other potential indications. The company has also initiated two undisclosed Phase II proof-of-concept studies involving CD38 (搜索) in autoantibody-driven diseases outside nephrology, Keeney said.
Pipeline Context and Commercial Infrastructure
Biogen has expanded into immunology and nephrology through transactions including its acquisition of HI-Bio (搜索) and its felzartamab asset. The company said its acquisition of Apellis added commercial products and nephrology capabilities, including medical and commercial infrastructure that could support a future felzartamab launch.
Chief financial officer Kramer said Biogen expects the Apellis transaction to be dilutive in 2026, primarily because of interest expense. Biogen has already implemented cost actions and expects annualized savings of roughly $250 million exiting next year, largely from research and development and general and administrative functions, while sales and medical organizations are being kept largely intact. Kramer said Biogen expects to pay down debt associated with the Apellis deal by the end of 2027.
For the coming year, Kramer said success would mean meeting growth portfolio commitments on revenue and earnings while preparing for potential launches in lupus and AMR.
Competitive and Strategic Considerations
Competition in the space spans established generic immunosuppressants and emerging biologics, so attention will focus on whether felzartamab offers clear added benefit in late antibody-mediated rejection (搜索). Success could widen Biogen's footprint in specialty nephrology and support premium pricing in a targeted population.
The longer runway of the extension study suggests limited near-term revenue impact but potential for a future label if data validate durable kidney protection. While the update alone is unlikely to move BIIB shares sharply, it adds to the pipeline depth narrative that can help support valuation during periods when core neurology franchises face pressure. The study remains ongoing, with further details available on the ClinicalTrials portal.
Broader Portfolio Dynamics
Biogen's growth portfolio more than offset erosion in the legacy multiple sclerosis (搜索) portfolio for most quarters in 2025, according to Kramer. In the second quarter, growth products excluding the two Apellis products exceeded the legacy MS portfolio.
Kramer said TYSABRI has shown resilience following biosimilar entry, which she attributed to the product's reputation among neurologists and patients, Biogen's patient-services organization and its FDA-approved JCV assay. Outside the U.S., the company also offers a subcutaneous formulation of TYSABRI.
Biogen expects continued contributions from its relationship with Roche and Genentech. Kramer noted that Roche recently launched a subcutaneous version of OCREVUS, which has shown traction. Biogen receives royalties tied to OCREVUS and participates in profit-sharing arrangements involving RITUXAN and GAZYVA. GAZYVA received U.S. and European approvals for lupus nephritis (搜索) this year, she said.
In spinal muscular atrophy (搜索), executives said SPINRAZA patient volumes have stabilized and that patients have transitioned rapidly from lower-dose treatment to the higher-dose option. Biogen also sees its acquired Alcyone device technology as a way to reduce administration barriers for certain patients receiving intrathecal therapies. The implanted device could allow SPINRAZA to be injected through a port rather than requiring a spinal tap for each quarterly administration, Keeney said.
Looking ahead, Keeney said Biogen expects to focus more on earlier-stage business-development opportunities through 2027, particularly in immunology, rare disease and neurology. He said the company is not financially constrained for early-stage transactions and could consider larger transactions as its balance sheet builds next year.